Palvella Therapeutics financials
$139.00−0.59%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$38.6M | -$14.1M |
| Net income | -$41.7M | -$17.4M |
| Net margin | — | — |
| Diluted EPS | $-3.71 | $-7.83 |
| EBITDA | -$38.6M | -$14.1M |
| Operating cash flow | -$25.0M | -$10.8M |
| Free cash flow | -$25.0M | -$10.8M |
| Diluted shares | 11.3M | 2.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $58.0M | $83.6M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 |
| Total assets | $59.6M | $88.2M |
| Total liabilities | $31.6M | $25.6M |
| Shareholders' equity | $28.0M | $62.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology